1011 related articles for article (PubMed ID: 29516216)
1. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
Nagai H; Muto M
Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.
Kottschade LA
Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902
[TBL] [Abstract][Full Text] [Related]
3. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.
Prieux-Klotz C; Dior M; Damotte D; Dreanic J; Brieau B; Brezault C; Abitbol V; Chaussade S; Coriat R
Target Oncol; 2017 Jun; 12(3):301-308. PubMed ID: 28540478
[TBL] [Abstract][Full Text] [Related]
6. Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities.
Renna CE; Dow EN; Bergsbaken JJ; Leal TA
J Oncol Pharm Pract; 2019 Jun; 25(4):954-960. PubMed ID: 30975067
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors for Indian patients: A note of caution.
Venniyoor A
Indian J Cancer; 2016; 53(3):468-469. PubMed ID: 28244488
[No Abstract] [Full Text] [Related]
8. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
Makarious D; Horwood K; Coward JIG
Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.
Wang GX; Kurra V; Gainor JF; Sullivan RJ; Flaherty KT; Lee SI; Fintelmann FJ
Radiographics; 2017; 37(7):2132-2144. PubMed ID: 29131763
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
12. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of advanced renal cell carcinoma: Current and future therapies.
Gill D; Hahn AW; Sonpavde G; Agarwal N
Hum Vaccin Immunother; 2016 Dec; 12(12):2997-3004. PubMed ID: 27494417
[TBL] [Abstract][Full Text] [Related]
14. [Immune-related adverse events of immune checkpoint inhibitors].
Tadano H; Torigoe T
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):102-108. PubMed ID: 28603200
[TBL] [Abstract][Full Text] [Related]
15. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
16. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
O'Kane GM; Labbé C; Doherty MK; Young K; Albaba H; Leighl NB
Oncologist; 2017 Jan; 22(1):70-80. PubMed ID: 27534573
[TBL] [Abstract][Full Text] [Related]
17. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
Koster BD; de Gruijl TD; van den Eertwegh AJ
Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management
.
Gordon R; Kasler MK; Stasi K; Shames Y; Errante M; Ciccolini K; Skripnik Lucas A; Raasch P; Fischer-Cartlidge E
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):45-52. PubMed ID: 28315555
[TBL] [Abstract][Full Text] [Related]
19. Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.
Aspeslagh S; Marabelle A; Soria JC; Armand JP
Chin Clin Oncol; 2015 Dec; 4(4):48. PubMed ID: 26730760
[TBL] [Abstract][Full Text] [Related]
20. Acute and Long-term Adverse Events Associated With Checkpoint Blockade.
Davies M
Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]